2 results
Approved WMOWill not start
Primary Objective: - To evaluate the efficacy of PF-06651600 and PF-06700841 at Week 8 in subjects with moderate to severe UC. Secondary Objective(s): - To evaluate the safety and tolerability of PF-06651600 and PF-06700841 in subjects with moderate…
Approved WMOPending
To compare invasive disease-free survival (iDFS) for ribociclib + ET versus placebo + ET in patients with HR-positive, HER2-negative, EBCwith high risk of recurrence.